Welcome to this week's Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please submit the good news or the bad from your shop, and we will feature it here at the end of each week.
Ogilvy and McCann heavyweight Andrew Schirmer has joined Syneos Health's GSW New York as president. Three members of the FDA panel that argued against aducanumab have quit in the wake of the Alzheimer's drug's approval. Inogen, recently equipped with a new CEO, has tapped BD vet Stanislav Glezer, M.D., as its chief medical officer.
(Lia Shaked)
Welcome to this week s Chutes & Ladders, our roundup of hirings, firings and retirings throughout the industry. Please submit the good news or the bad from your shop, and we will feature it here at the end of each week.
Verily
(FDA)
Amy Abernethy, M.D., is the latest former government official to join Verily, the Alphabet subsidiary announced Thursday.
It was only a few months ago that she departed from her role as principal deputy commissioner of food and drugs at the Food and Drug Administration (FDA). She also served as the agency’s acting chief information officer.
Novartis has lost another NIBR exec to the call of biotech. Blueprint Medicines has added another BMS vet to its roster. And Iovance quietly announced its CEO's departure Wednesday.
by Kyle LaHucik |
May 19, 2021 9:55am Another Novartis R&D leader exits the Swiss pharma giant to take on an executive role at a biotech startup. (Pixabay)
Novartis Gopi Shanker, Ph.D., is the latest R&D leader to exit the Swiss pharma giant as he takes up the helm of chief scientific officer at gene therapy startup Tevard Biosciences.
Shanker follows the exit of Jeff Engelman M.D., Ph.D., who left the Novartis Institutes for Biomedical Research (NIBR) in late-April to form a new cancer biotech, Treeline Biosciences. Days later, Peter Hammerman, M.D., Ph.D., exited to start as chief scientific officer of “molecular machines” biotech MOMA Therapeutics. Both Engelman and Hammerman focused on oncology R&D for the Big Pharma.